Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
RESEARCH TOOLSreports
Holding TRVI?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2019
|% Change Since: 21.29%
|Next Earnings Date:Aug 12, 2019
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a strong financial position with a substantial cash runway, which are positive indicators. However, these are tempered by an increased net loss and uncertainty regarding clinical outcomes, particularly in the IPF trial's SSRE analysis.Company Guidance
During the third quarter 2024 earnings call for Trevi Therapeutics (TRVI), the company provided guidance on several upcoming milestones and financial metrics. Trevi anticipates releasing data from their Human Abuse Potential (HAP) study in December 2024, followed by a sample size re-estimation (SSRE) in their IPF chronic cough trial by the year's end. Financially, Trevi reported a net loss of $13.2 million for the quarter, an increase from the $7.7 million loss in Q3 2023, driven by heightened R&D expenses totaling $11.2 million. The company maintains a cash runway into the second half of 2026, with cash, cash equivalents, and marketable securities standing at $65.5 million as of September 30, 2024. Trevi's projected cash burn for 2024 is expected to be between $41 million and $43 million. Looking ahead to 2025, Trevi plans to release data from their Phase IIa RIVER trial in RCC in Q1 and the full CORAL Phase IIb study in the first half of the year, contingent on the SSRE outcomes.Progress in Clinical Trials
Significant progress in clinical trials including IPF chronic cough and RCC trials with upcoming data milestones. HAP study results expected in December 2024, CORAL Phase IIb SSRE by year-end, and RIVER Phase IIa top line data in Q1 2025.
Financial Position and Cash Runway
As of September 30, 2024, Trevi Therapeutics had cash, cash equivalents, and marketable securities totaling $65.5 million, with a cash runway projected into the second half of 2026.
Introduction of Experienced CDO
Jim Cassella, with over 35 years of experience in CNS therapies, joined Trevi as Chief Development Officer, bringing invaluable expertise for late-stage development.
---
TRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $3.10 | $2.90 | -6.45% |
| Aug 08, 2024 | $2.80 | $2.86 | +2.14% |
| May 07, 2024 | $2.90 | $2.64 | -8.97% |
| Mar 20, 2024 | $3.54 | $3.70 | +4.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Trevi Therapeutics Inc (TRVI) report earnings?
Trevi Therapeutics Inc (TRVI) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is Trevi Therapeutics Inc (TRVI) earnings time?
Trevi Therapeutics Inc (TRVI) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRVI EPS forecast?
TRVI EPS forecast for the fiscal quarter 2024 (Q4) is -0.12.
---